<DOC>
	<DOCNO>NCT01542632</DOCNO>
	<brief_summary>A Phase 1 study compare safety , tolerability immunogenicity different dose schedule subcutaneously ( SC ) administer dengue vaccine healthy adult compare immunogenicity different dose schedule vaccine . Blood sample obtain safety lab Days 0 , 7 , 14 , 90 , 97 , 104 measurement viremia baseline [ screening period day vaccination ( Day 0 ) ] , Days 7 , 9 , 11 , 14 , 17 , 21 , 90 , 97 , 104 . Blood sample measurement dengue neutralizing antibody serum obtain baseline [ screen period day vaccination ( Day 0 ) ] , Days 30 , 90 120 . The entire duration individual subject participation approximately 5 month include recruitment collection data primary outcome ( Day 120 ) .</brief_summary>
	<brief_title>A Comparison Safety Immunogenicity Various Schedules Dengue Vaccine Healthy Adult Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Dengue</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Male female least 18 year ≤ 45 year old time screen 2 . In good health determine medical history , physical examination include height weight 3 . Normal clinical safety laboratory examination [ Sodium ( Na ) , Potassium ( K ) , Glucose , Blood Urea Nitrogen ( BUN ) , creatinine , Alanine aminotransferase ( ALT ) , Aspartate aminotransferase ( AST ) , total bilirubin , White Blood Cell ( WBC ) , neutrophil count , hemoglobin , platelet , Prothrombin Time ( PT ) , Partial Thromboplastin Time ( PTT ) , urinalysis ( dipstick ) ] . 4 . Weight : Body Mass Index ( BMI ) ≤32 5 . Blood test negative antibody Human Immunovirus ( HIV1 ) , Hepatitis C , Hepatitis B surface antigen 1 . Any condition would limit subject 's ability complete study opinion Investigator 2 . Clinically significant ECG finding 3 . History significant dermatologic disease last 6 month , 4 . History diabetes mellitus 5 . History recur headache migraine ( frequent per week ) prescription medication treatment recur headache migraine 6 . Hypersensitivity vaccine 7 . Receipt vaccine 4 week precede first vaccination 8 . Planned receipt vaccine 4 week follow vaccination study 9 . Known history Japanese Encephalitis Virus ( JEV ) and/or Yellow Fever ( YF ) 10 . Previous vaccination ( clinical trial approve product ) flaviviruses include dengue , yellow fever ( YF ) Japanese Encephalitis ( JE ) 11 . Seropositivity dengue West Nile ( WN ) virus 12 . Known suspected congenital acquire immunodeficiency , immunosuppressive therapy anticancer chemotherapy radiation therapy within precede 6 month 13 . Use within previous 6 month systemic corticosteroid therapy ( dose least 0.5 mg/kg/day ) . Topical prednisone permit currently use within last 3 month . Note , inhale prednisone ( equivalent ) allow 14 . Use nonsteroidal antiinflammatory drug ( NSAIDs ) , acetaminophen antihistamine 3 day immediately prior vaccination 15 . Use prescription counter medication ( besides specifically mention require medical management concurrent disease ) 7 day first vaccination ( Day 0 ) 16 . Positive urine screen cocaine , amphetamine , opiate , cannabinoids 17 . Donation blood 6 week first dose ( ) ( Day 0 ) 30 day dose day 90 18 . Females pregnant lactating</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>safety immunogenicity dengue vaccine</keyword>
</DOC>